EXPLOITATION OF NEW DIAGNO-THERAPEUTIC PROCEDURES OF HUMAN UTERINE CANCER BASED ON MOLECULAR CYTOGENETIC STUDY

在我们的研究所，罕见的临床材料，从子宫颈和子宫内膜腺癌可用于几个调查。我们在分子细胞遗传学研究的基础上探讨了人类子宫癌诊断和治疗的新方法。基于阵列的宫颈腺癌CGH分析显示LRP 1B（2q21.2）、DAB 2（5 p13）和DCC（18q21.3）的拷贝数减少。这些基因改变可能是宫颈腺癌特有的，可能参与了癌变过程。由于子宫癌的化疗通常是有效的，手术或放射治疗结合新辅助和/或辅助化疗预计将显着改善患者的所有生存期。因此，任何化疗敏感性的预测可能有助于治疗决策相关的切换从手术到放射治疗等最近，子宫内膜癌的发病率高的妇女遗传性非息肉病性结直肠癌（HNPCC）的报道，这表明家族性子宫内膜癌和HNPCC之间的关系。家族性子宫内膜癌仅占所有子宫内膜癌的0.5%，详细检查家族史是必要的。我们对符合HNPC相关子宫内膜癌家族易感性标准的子宫内膜癌患者进行了三种DNA错配修复（MMR）基因（hMLH 1、hMSH 2和hMSH 6）的突变分析。

In our institute, rare clinical materials from both endocervical and endometrial adenocarcinomas are available for several investigations. We investigated new diagno-therapeutic procedures of human uterine cancer based on molecular cytogenetic study. The array-based CGH analysis of endocervical adenocarcinomas revealed decreasing copy numbers in LRP1B (2q21.2) DAB2 (5p13), and DCC (18q21.3). These genetic changes are presumably specific to the endocervical adenocarcinomas, which may be engaged in the carcinogenesis. As the chemotherapy for uterine cancers is usually effective, surgical or radiation therapy combined with neoadjuvant and/or adjuvant chemotherapy is expected to improve significantly over all survival of the patients. Therefore, any prediction of chemotherapeutic sensitivity may be helpful for therapeutic decisions associated with switching from surgery to radiation therapy and so forth.Recently, a high rate of endometrial cancer has been reported in women with hereditary nonpolyposis colorectal cancer (HNPCC), suggesting a relation between familial endometrial cancers and HNPCC. Familial endometrial cancers constitute only about 0.5% of all endometrial carcinomas and it is essential to examine family histories in detail. We performed a mutational analysis of three DNA mismatch repair (MMR) genes (hMLH1, hMSH2 and hMSH6) in patients with endometrial cancer who meet our criteria for familial predisposition to HNPCC-associated endometrial cancers.